看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。, {$ z/ k q- g, W
" Z) d* U7 s; v$ ~2 D/ f
6 j5 ]# @% [. x% |+ k, X- JCurrently available feasibility data for possible combination strategies.
7 N& h6 B9 Q: o/ L h& \————————————————————————————————* y* k1 s% H" x/ b. H+ N$ u
Combination Feasibility according to preliminary data
# l0 a; N, p% r# `3 O1 B7 k——————————————————————————————————
3 ~) `# d/ U; ^9 SBevacizumab + sorafenib Yes, reduced dose 0 Q E* c7 C1 O9 u0 c9 T7 K% X6 I
Bevacizumab + sunitinib† No . h4 r+ t4 d; ~4 u% I& x
Bevacizumab + temsirolimus Yes n! L- Q; E9 L. b
Bevacizumab + everolimus Yes ! x* B$ h5 w. i: N |/ J% @9 U
Sorafenib + sunitinib ? - v9 f, g; @* `0 }# p3 X
Sorafenib + temsirolimus Yes, reduced dose
- Q- t r/ j3 A1 u9 V' SSorafenib + everolimus Yes, reduced dose
( y" x- H( Y! h; u' i! k& k& n$ ~Sunitinib + temsirolimus† No
) H4 S( F+ u) c- S1 ASunitinib + everolimus ? 1 }: _, {; S1 C$ ]4 K, X2 u) q
Temsirolimus + everolimus ? & I" _# h* M3 R* T, h
————————————————————4 H, |9 L- @! s
†Led to US FDA warning.
% U' D$ P3 s3 ~% T) I0 G A?: As yet unattempted combination.$ k4 T, i0 w! J' E
|